The cardiovascular system, the very lifeline of our bodies, is vulnerable to a myriad of disorders. With an aim to mend these vulnerabilities, Infensa has been pioneering the realm of peptide drugs. Their flagship compound, IB001, emerges as a beacon of hope for countless patients. Operating as a potent and selective inhibitor of human ASIC1a, IB001 holds the potential to shield neurons and heart muscle cells from the devastating effects of ischemic injuries. Through their dedication, Infensa seeks to rewrite the narrative of cardiovascular health.